Author: Yang, Feifei; Wang, Jiali; Jiang, Lin; Jin, Jialin; Shao, Lingyun; Zhang, Ying; Zhang, Jiming; Weng, Xinhua; Chen, Shu; Zhang, Wenhong
Title: A fatal case caused by novel H7N9 avian influenza A virus in China Document date: 2013_4_10
ID: xt38fwtt_4
Snippet: To date, the overall proportion of fatal cases among those reported 21 cases was 28.6% (6/21), lower than that in H5N1 AIV infection in humans (average 59%). 7 According to the experience from H5N1 AIV treatment, cases with a fatal outcome were admitted to hospital later (median, 5 days) than those who survived (median, 1 day). 7 All fatal cases in Shanghai including this patient were admitted to hospital very late until the symptom of shortness .....
Document: To date, the overall proportion of fatal cases among those reported 21 cases was 28.6% (6/21), lower than that in H5N1 AIV infection in humans (average 59%). 7 According to the experience from H5N1 AIV treatment, cases with a fatal outcome were admitted to hospital later (median, 5 days) than those who survived (median, 1 day). 7 All fatal cases in Shanghai including this patient were admitted to hospital very late until the symptom of shortness of breath developed. Meanwhile, due to unclear cause of the disease, fatal cases, including this patient, had not been given the anti-influenza drugs such as neuraminidase inhibitors (oseltamivir) as soon as possible and within 2,4 days of disease onset, leading to loss of valuable salvage time for the severe cases. Since the laboratory testing conducted in China has shown that the influenza A (H7N9) viruses are sensitive to oseltamivir and zanamivir, and if these drugs are given early in the course of illness and the patients are hospitalized earlier, the survival rate of this new emerging infectious disease might be significantly improved. Future strategies to prevent fatal cases should include prompt laboratory diagnosis and early antiviral and steroid treatment, and good supportive care.
Search related documents:
Co phrase search for related documents- AIV treatment and survival rate: 1
- anti influenza drug and survival rate: 1
- breath shortness and disease onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- breath shortness and disease onset day: 1
- breath shortness and early antiviral: 1, 2, 3
- breath shortness and fatal case: 1, 2, 3
- breath shortness and fatal outcome: 1, 2, 3, 4, 5, 6, 7
- breath shortness and future strategy: 1
- breath shortness and illness course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- breath shortness and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- breath shortness and laboratory diagnosis: 1, 2, 3, 4, 5, 6, 7
- breath shortness and laboratory testing: 1, 2, 3, 4, 5, 6, 7, 8, 9
- breath shortness and late hospital: 1, 2
- breath shortness and later hospital: 1, 2, 3, 4, 5, 6
- breath shortness and overall proportion: 1
- breath shortness and patient include: 1
- breath shortness and severe case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
- breath shortness and significantly improve: 1, 2, 3
- breath shortness and supportive care: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Co phrase search for related documents, hyperlinks ordered by date